A first-in-human phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody.

Jeffrey Yachnin,Gustav Ullenhag,Ana Carneiro,Dorte Nielsen,Kristoffer Staal Rohrberg,Anne Månsson Kvarnhammar,Lena Schultz,Erika Bågeman,Camilla Wennersten,Charlotte A. Russell

A first-in-human phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody.

2020

Jeffrey Yachnin
Gustav Ullenhag
Ana Carneiro
Dorte Nielsen
Kristoffer Staal Rohrberg
Anne Månsson Kvarnhammar
Lena Schultz
Erika Bågeman
Camilla Wennersten
Charlotte A. Russell

3061Background: ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody developed to be a next generation CTLA-4 antibody with enhanced immune activation and tumor-directed activity f...

Keywords:

first in human
phase i study
Refractory
in patient
Pathology
bispecific antibody
Medicine
CTLA-4
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations